Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OMED

OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis

OncoMed Pharmaceuticals logo

About OncoMed Pharmaceuticals Stock (NASDAQ:OMED)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$0.89
52-Week Range
N/A
Volume
1,201 shs
Average Volume
768,904 shs
Market Capitalization
$34.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive OMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OMED Stock News Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
Bispecific Antibody Market Size | Statistics By 2031
See More Headlines

OMED Stock Analysis - Frequently Asked Questions

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to the consensus estimate of $7.97 million. OncoMed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.14% and a negative net margin of 18.24%.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS).

Company Calendar

Last Earnings
11/01/2018
Today
7/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OMED
CIK
1302573
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.10 million
Net Margins
-18.24%
Pretax Margin
N/A
Return on Equity
-13.14%
Return on Assets
-7.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.04
Quick Ratio
5.04

Sales & Book Value

Annual Sales
$44.42 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
38,690,000
Free Float
N/A
Market Cap
$34.43 million
Optionable
Optionable
Beta
1.86
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:OMED) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners